Linker Information
General Information of This Linker
| Linker ID |
LIN0KRNAQ
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Beta-Glucuronidase cleavable linker
|
|||||
| Linker Type |
Beta-glucuronidase-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
SGN-CD48A [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03379584 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
75.00%
|
Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | EJM cells | CVCL_2030 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
87.50%
|
Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | U-266 cells | CVCL_0015 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
100.00%
|
Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.00-11.00 ng/mL
|
High CD48 expresion (CD48+++/++; 1260 MSLN molecules/cell) | ||
| Method Description |
Cytotoxic activity of SGN-CD48A was demonstrated in a panel of human MM cell lines in vitro.
|
||||
| In Vitro Model | Multiple myeloma | Multiple myeloma cells | Homo sapiens | ||
SGN-CD228A [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04042480 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 study of SGN-CD228A in select advanced solid tumors.
|
||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
75.00%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 3.00 mg/kg.
|
||||
| In Vivo Model | NSCLC PDX model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
100.00%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | NSCLC PDX model | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
50.00%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Melanoma CDX model | ||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-5 cells | CVCL_0527 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
62.50%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Melanoma CDX model | ||||
| In Vitro Model | Cutaneous melanoma | COLO 853 cells | CVCL_2003 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
100.00%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Squamous NSCLC CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | Calu-1 cells | CVCL_0608 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.